Luxembourg, Luxembourg

Elisabeth Letellier

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2023

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Elisabeth Letellier in Cancer Diagnosis

Introduction

Elisabeth Letellier is a notable inventor based in Luxembourg, LU. She has made significant contributions to the field of cancer diagnosis through her innovative research and patented methods. Her work focuses on the identification of biomarkers that can aid in the diagnosis, prediction, and staging of various types of cancer.

Latest Patents

Elisabeth Letellier holds one patent titled "Biomarkers for cancer diagnosis, prediction or staging." This invention relates to a method for predicting clinical outcomes for subjects diagnosed with colorectal cancer, skin cancer, head and neck cancer, or lung cancer. Additionally, it provides a method for predicting whether a subject has a predisposition to develop such cancers, as well as a method for aiding in the staging of these cancers. The methods utilize biomarkers such as MYO5B and/or RAB8A, and may also include RAB9A, RAB10, RAB11A, RAB25, CDC42, RAC, and/or RhoA.

Career Highlights

Throughout her career, Elisabeth Letellier has worked with esteemed institutions, including the University of Luxembourg. Her research has been pivotal in advancing the understanding of cancer biomarkers and their applications in clinical settings.

Collaborations

Elisabeth has collaborated with notable colleagues such as Martine Schmitz and Aurelien Ginolhac. Their joint efforts have contributed to the development of innovative solutions in cancer research.

Conclusion

Elisabeth Letellier's work exemplifies the impact of innovation in the medical field, particularly in cancer diagnosis and treatment. Her contributions through patented methods are vital for improving clinical outcomes for cancer patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…